The aim of our study was to assess the efficacy of extracorporeal photopheresis (ECP) in chronic graft-versushost disease (GVHD). Eleven patients with chronic cutaneous GVHD were studied. Four had mucosal involvement and five had pulmonary involvement. All had failed to improve on first-and second-line therapy. Three patients received ECP alone; the remainder continued to receive steroids and/or immunosuppressive therapy. Patients received ECP twice monthly for 4 months and then once monthly for 3 months. They were evaluated by serial skin scores, mucosal and skin photography, pulmonary function tests, biochemical and haematological parameters. Nine patients showed objective evidence of cutaneous improvement with a mean reduction in skin score of 48% overall. In the 10th patient, skin scores and oral involvement improved on twice monthly ECP but deteriorated when reduced to once monthly. The final patient died from renal failure secondary to cyclosporin toxicity. Two out of five patients with lung involvement showed a mild improvement in pulmonary function tests. Liver function tests were abnormal in five patients; they improved in one and deteriorated in three. All patients receiving concomitant immunosuppressive/steroid therapy were able to reduce drug dosages by trial completion. Our results indicate that ECP can benefit patients with cutaneous and mucosal chronic GVHD who have failed on firstand second-line therapies. The effect on the systemic manifestations of GVHD is less consistent.
morbidity and mortality. Acute GVHD affects 40-50% of allogeneic stem cell transplant recipients and chronic GVHD affects 30-50% of those surviving the acute phase of transplantation. 1, 2 Prevention of GVHD is important because treatment of established disease is often unsatisfactory. Measures such as pre-transplant T cell depletion and immunosuppression with methotrexate, cyclosporin A and prednisolone are routinely undertaken.
Chronic GVHD may be limited to localised skin involvement and liver dysfunction, or the disease may be more extensive with generalised skin involvement and additional organ involvement. Patients with limited disease may not require any treatment; however, those with extensive disease require treatment to decrease the chance of progression to end stage disease. Many patients respond to oral glucocorticoids 3 and others respond to a combination of oral glucocorticoids and cyclosporin A. 4 Refractory chronic GVHD has been successfully treated with other agents including azathioprine, thalidomide 5 and photochemotherapy in the form of PUVA. [6] [7] [8] [9] [10] There have also been a number of anecdotal case reports [11] [12] [13] and small studies 14, 15 reporting the success of extracorporeal photopheresis (ECP).
The aim of our study was to assess the safety and efficacy of UVAR/UVADEX ECP (Therakos UK, Bracknell, UK), in the treatment of patients with skin manifestations of chronic GVHD which had failed to respond to standard therapies.
Patients and methods
Eleven adult patients of median age 40 years (range 18-47 years) were studied. All had received HLA-matched bone marrow transplants for haematological malignancies, from sibling (n = 8) or unrelated (n = 3) donors. They were recruited nationally from Haematology and Dermatology departments within the United Kingdom. They were treated at two centres: the Department of Haematology, Rotherham District General Hospital (patients 1-6) and St John's Institute of Dermatology, St Thomas' Hospital, London (patients 7-11). Informed consent to take part in the study was obtained from all patients and approval from the local ethics committees had been granted. All patients had chronic cutaneous GVHD, and all had failed to respond to conventional immunosuppressive protocols. All patients had at least one of the following clinical features:
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(1) skin thickening, sclerosis, hyper-or hypo-pigmentation, or ulceration; (2) joint contractures or fascial thickening; (3) oral ulceration; (4) lichenoid skin changes.
The clinical data on all patients enrolled in the study are shown in Table 1 . The median time from onset of chronic GVHD to start of ECP therapy was 17 months (range 5-59 months). Five patients had AML, three had ALL, two had CML and one had multiple myeloma. Four patients had mucosal involvement and five had pulmonary involvement. Three patients received ECP alone (patients 2, 3 and 8); the remainder received additional steroids and/or immunosuppressive therapy. Two were treated with prednisolone alone (patients 7 and 10), two with prednisolone and cyclosporin A (patients 6 and 11), patient 4 was taking prednisolone and azathioprine, patient 5 was taking azathioprine and cyclosporin A and the other 2 patients (1 and 9) were taking a combination of prednisolone, azathioprine and cyclosporin A.
The following criteria were also fulfilled: haemoglobin Ͼ9 g/dl, platelets Ͼ20 × 10 9 /l, neutrophils Ͼ1 × 10 9 /l; body weight of Ͼ40 kg and adequate cardiac function to tolerate ECP.
ECP procedure
Using the UVAR/UVADEX (liquid methoxsalen) system (Therakos UK) this involved collection of leukocyteenriched blood, photoactivation and then reinfusion of the blood. Venous access was obtained peripherally or via a Hickman line and aliquots of whole blood were removed. Three hundred millilitres of plasma and 240 ml of buffy coat were separated and saved in six cycles of blood collection, centrifugation and reinfusion. During each cycle, whole blood was centrifuged and separated in a paediatric Table 1 Clinical data on all patients enrolled in the study pheresis bowl, saving the plasma and buffy coat layers. Forty millilitres of buffy coat and a volume of plasma were collected during each cycle. The red blood cells and all additional plasma were reinfused into the patient before beginning the next collection cycle. Two hundred microgrammes of UVADEX were injected into the buffy coat bag at the end of the first cycle. Photoinactivation of the leukocyte-enriched blood began during the first cycle of buffy coat collection. Plasma and buffy coat were mixed with 200 ml of heparinized saline, followed by pumping of the mixture continuously through the photoactivation chamber where they were exposed to UVA light; the tubing within the chamber was of uniform thickness, allowing homogenous penetration of the UVA. During the irradiation phase, UVADEX is activated by UVA light, with concomitant pyrimidine base cross-linking of DNA in the leukocytes. The total photopheresis process took 3-4 h and treatment was performed on 2 consecutive days.
Treatment protocol
Patients were treated with ECP twice monthly for the first 4 months and were assessed clinically at 0, 4, 8 and 14 weeks. Wherever possible patients were kept on a constant dose of concomitant immunosuppressive therapy. After 4 months, ECP was continued once monthly for a further 3 months. Those who continued to improve were maintained on monthly ECP following completion of the study.
Cutaneous evaluation
Skin involvement was assessed by a member of the team trained in the appropriate method of skin scoring. All members involved in skin scoring had received a common training. Each individual patient was skin scored by the same team member at each visit. Assessments were carried out at 0, 4, 8 and 14 weeks, 6 months and at study completion. Skin biopsies were taken from representative areas prior to starting ECP to confirm the presence of predominantly lichenoid or sclerodermoid histological features. However, histology was not used to assess the effect of ECP as sclerodermoid changes are difficult to grade histologically. Lichenoid changes histologically were represented clinically by either erythema and scaling or papules. Therefore skin scores were assessed clinically according to the following protocol:
(1) Erythematous and lichenoid eruptions: area skin score:
percentage of body surface or cm diameter of isolated lesions. Grading of erythema: 0 = no lesions, 1 = erythema or lichenoid lesions, 2 = both erythema and lichenoid lesions. Serial clinical photographs were also used to assess both cutaneous and oral disease throughout the study.
Pulmonary function tests
Including FEV 1 , FVC and CO transfer were assessed at weeks 0, 14 and 20.
Laboratory analyses
Full blood count, urea and electrolytes, and liver function tests were measured at baseline and at each subsequent visit.
Results
Eight patients completed the study. One patient (patient 11) died from renal failure secondary to cyclosporin A toxicity following one cycle of ECP. A second patient (patient 9) developed pneumonia after eight cycles and ECP was stopped; however, it was subsequently restarted with no adverse effects. A third patient (patient 3) withdrew from the trial after 4 months treatment because of reduced mobility following a septic arthritis; he found it difficult to attend hospital for ECP and was subsequently commenced on mycophenolate mofetil with no deterioration in his GVHD.
Skin disease
All 10 evaluable patients had a reduction in skin score over the study period (Table 2) ; five patients showed a greater consecutive fall in skin scores when treated twice monthly as compared with once monthly; skin scoring in patient 10 improved on twice monthly ECP but deteriorated when reduced to once monthly ( Figure 1 ). Overall, there was a 48% reduction in skin score (range 16.5-95%). Patient 3 only achieved a 16.5% reduction in skin score, however he had withdrawn from the trial after 4 months. Patient 5 experienced an almost complete response. Figure 2 illustrates the improvement in skin disease in patient 2 who achieved a 63% reduction in skin score by study completion. Six patients were able to reduce their dose of concomitant prednisolone (patients 1, 4, 6, 7, 9, 10); the dose of cyclosporin A was also reduced in patient 1 and the dose of azathioprine was reduced in patient 5. In one patient the dose of prednisolone was temporarily increased (patient 10) and in this instance evaluation was carried out when the dosage had been reduced to the pre-ECP level. No patient's skin score deteriorated whilst on ECP.
Mucosal disease
Four patients had mucosal disease. Mucositis improved in patient 4. The improvement in ocular disease in patient 9 allowed him to be maintained subsequently on a lower steroid dosage. There was a marked improvement in oral disease in patient 10 when receiving twice monthly ECP ( Figure 3 ) but it deteriorated when reduced to once monthly.
Pulmonary disease
Five patients had lung involvement with marked restrictive defects and reduced gas transfer. Patients 4 and 6 showed an improvement in gas transfer during the study period (20% and 25% respectively); however there was no change in their restrictive defect. Results of pulmonary function tests did not alter in patients 1 and 2. Patient 3 had a mild restrictive defect and reduced gas transfer at baseline; however, his pulmonary function tests were not repeated. No deterioration in pulmonary function was noted in the patients with normal lung function at the start of the study.
Hepatic involvement
Liver function tests (LFTs) were abnormal in six patients (Table 3) . None of the patients had undergone a liver biopsy prior to ECP. During treatment LFTs improved in one patient, and deteriorated in three patients. Patient 9 experienced a marked deterioration in liver function whilst on ECP. He had been taking regular paracetamol for back pain and this was discontinued. He was also noted to have a high ferritin level. A genetic test for haemachromatosis was negative and his abnormal LFTs were attributed to a combination of GVHD and iron overload. He refused a liver biopsy.
Haematological indices
No changes in full blood count were seen in any patient throughout the study. Patient 3 entered the study with a platelet count of 24 × 10 9 /l. No increase in platelet count was observed throughout his treatment period.
Other features
Patient 6 noticed a marked improvement in his joint contractures. Maximum range of movement of the knee joints Table 2 Skin scores and percentage reduction in skin score for each patient over the study period were measured at regular intervals throughout the trial period. The distance from the anterior iliac crest to the lateral malleolus at full flexion and full extension were measured for each leg. On the left, the range of movement improved from 6 cm to 32 cm and on the right it improved from 9 cm to 30 cm, at study completion.
Side-effects
All patients tolerated ECP well. Mild hypotension during apheresis occurred in patient 1 on one occasion. Patient 9 developed pneumonia. He was also taking steroids and cyclosporin A and it was not thought to be as a result of ECP.
Outcome following study period
Patient 1 continued monthly ECP with further gradual reduction in skin scoring (percentage reduction after 18 months 69.5%). However, he developed recurrent chest infections and died from pneumonia caused by Aspergillus. Patient 2 remains on monthly ECP. His skin scores have continued to fall (85% reduction in skin score over 15 month period). However, his respiratory disease has not improved and he was commenced on glucocorticoids 3 months ago. Patient 4 also continues monthly ECP (74% reduction in skin score after 18 months); his liver function tests remain stable and his respiratory disease remains unchanged. The excellent response in the skin disease in patient 5 is being maintained with monthly ECP. Patient 6 continued ECP for a total of 1 year (67% reduction in skin score); it was stopped because of poor venous access and recurrent Hickman line infections. Patient 8 stopped ECP following the trial at his request. Patient 10 stopped ECP because the benefit he gained when receiving twice monthly treatment was not maintained on once monthly treatment and he was unable to attend fortnightly. Patient 9, with iron overload, stopped ECP because of limited venous access and the requirement for regular venesection.
Discussion
Our study involved 11 patients with chronic cutaneous GVHD who had already failed first-and second-line therapy. In spite of this an overall improvement of 48% was observed during the trial period. In the majority of patients the improvement in skin disease was greater over the first 4 months when they were receiving ECP twice monthly (Figure 1) . In patients who continued ECP after the study period, further improvement continued with virtually complete resolution of cutaneous disease in one patient at 18 months. A further benefit gained from the study was that all patients not receiving ECP alone were able to reduce Patient 11 had abnormal liver function tests at baseline but they were not repeated as she only received one cycle of ECP.
the dose of their concomitant steroid/immunosuppressive therapy. Improvement in mucosal disease occurred in three out of four patients. However, the effect of ECP on the visceral manifestations of chronic GVHD, in particular liver and pulmonary disease, was not so consistent. Two out of the five patients with pulmonary disease showed a small improvement in gas transfer but no patient showed improvement in their restrictive defects on pulmonary function testing. Lung function did not deteriorate in any patient during the trial period. However, one patient died of pneumonia secondary to ongoing chronic graft-versus-host disease affecting the lungs in spite of a 69.5% reduction in skin score over the 18 month treatment period. Hepatic involvement, assessed by serial liver function tests, which were abnormal in six patients, improved in only one patient and deteriorated in three. Liver biopsies were not performed in any of the patients. Consequently, other factors leading to abnormal LFTs, such as drug-induced damage, could not be assessed.
Our results should be compared with a separate study of ECP recently completed in Austria. 15 This used a similar treatment protocol in 13 patients with drug-resistant chronic GVHD. In eight patients there was almost complete resolution of skin lesions with a marked improvement in a further three. Mucosal ulceration resolved in 10 out of 12 patients. This study also demonstrated a benefit on liver enzymes with serum alkaline phosphatase normalising in seven out of 12 patients, but pulmonary involvement was not measured. The Austrian study compliments our findings in skin and mucosal disease and indicates a systemic benefit in some patients. This may relate to the timing of ECP therapy. In cutaneous T cell lymphoma, patients who are immunocompromised do not respond so well to therapy with ECP. 16 Therefore, other studies have suggested that ECP may be more beneficial when started earlier in the disease.
14 In our own study the median time from onset of GVHD to start of therapy was 17 months, but in those patients whose skin scores improved Ͼ50% the median time was only 10 months.
ECP is expensive and relatively invasive but all patients in our study tolerated the procedure with minimal sideeffects. Venous access can be a problem, particularly in patients with severe sclerodermoid changes. In this situation ECP can be performed with a single lumen 13.5 gauge Hickman line. However, the one patient who required an indwelling catheter had to discontinue ECP because of recurrent Hickman line infections. Although our study was confined to adults, ECP has been used successfully in children with GVHD. 14 ECP has advantages over PUVA which is known to increase the incidence of non-melanoma skin cancer and possibly melanoma. 17, 18 PUVA therapy cannot be used to treat ocular disease because of the risk of cataract formation. It can be used to treat mucosal disease in the mouth but this treatment is difficult to administer and not widely available. PUVA has no effect on systemic disease, whereas ECP at least has the potential to benefit organs other than the skin. Nausea following administration of oral psoralens is eliminated by addition of the psoralen (UVADEX) directly into the buffy coat prior to UVA irradiation. A second advantage of using UVADEX is avoidance of inter-and intraindividual variability in the gastrointestinal absorption of psoralen. 19 PUVA is administered twice weekly necessitating more frequent hospital visits. However, the availability of ECP is limited with only three centres in the UK at present. Some patients have to travel long distances for treatment each month making this form of therapy less attractive.
ECP was used initially in the management of cutaneous T cell lymphoma as an alternative method of photochemotherapy to PUVA. 20 Subsequently, several autoimmune T cell-mediated processes have been treated successfully, including pemphigus vulgaris, 21 systemic lupus erythematosus 22 and scleroderma. 23 It has also been reported as effective in the prevention of solid organ transplant rejection. 24 The mechanism by which ECP is thought to work is not fully understood. Exposure to 8-methoxypsoralen in the extracorporeal system induces photoactivation of the cells in the buffy coat. Psoralens intercalate with the DNA base pairs to form pyrimidine dimers after UVA irradiation, leading to DNA damage which may account for the mutagenic and antiproliferative effect. The mechanism of action cannot be explained fully by this as only 5-10% of leucocytes are exposed to psoralen and UVA during ECP. A further possible explanation is that the treatment triggers an immunomodulatory response to pathologically altered T cells; 25 it increases the immunogenicity of class 1-associated peptides on the surface of pathogenic T cells, enhancing the regulatory action of CD8+ve cytotoxic T cells with specificity for those antigens. 26 ECP can also affect TH1/TH2 ratios. 27 However, our studies using a novel single cell cytokine assay showed no effect of ECP on TH1/TH2 ratios in patients with chronic cutaneous GVHD. 28, 29 Our results indicate that ECP can benefit patients with cutaneous and mucosal chronic GVHD who have failed to improve on first-and second-line therapies. The effect of ECP on the visceral manifestations of chronic GVHD is less consistent. Ideally, ECP should be used before secondline therapy with immunosuppressive agents which may obscure its immuno-modulatory effects. Furthermore, larger, randomised international studies are required in order to recruit sufficient numbers of patients. If its therapeutic benefit can be reproduced in a randomised study, ECP should become a useful and relatively safe treatment modality in the management of chronic cutaneous GVHD.
